When the pandemic struck in 2020, Chubb and legal partner Kennedys produced a series of reports exploring the impact it was having on the life science industry through the lenses of clinical trials, medical devices, telehealth, genomics and the supply chain.
Two years on, we take stock, looking at how those changes played out in the medium term. Which innovations have become part of the new normal and where did things go wrong? From the new strength and capacity that has been built in telehealth and clinical trials, to the lessons that have been learnt for future pandemics on medical devices and supply chains.
View our final report of the series.